Compare COOK & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COOK | PRME |
|---|---|---|
| Founded | 1985 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Wholesale Distributors | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.4M | 536.4M |
| IPO Year | 2021 | 2022 |
| Metric | COOK | PRME |
|---|---|---|
| Price | $58.44 | $3.11 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $53.00 | $7.56 |
| AVG Volume (30 Days) | 64.0K | ★ 2.7M |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.18 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $559,520,000.00 | $4,632,000.00 |
| Revenue This Year | N/A | $7.06 |
| Revenue Next Year | $3.07 | $47.01 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 55.28 |
| 52 Week Low | $0.48 | $2.67 |
| 52 Week High | $86.59 | $6.94 |
| Indicator | COOK | PRME |
|---|---|---|
| Relative Strength Index (RSI) | 40.64 | 46.92 |
| Support Level | $55.71 | $2.73 |
| Resistance Level | $71.83 | $3.60 |
| Average True Range (ATR) | 4.66 | 0.18 |
| MACD | -0.48 | 0.03 |
| Stochastic Oscillator | 32.35 | 61.34 |
Traeger Inc designs, sources, sells, and supports wood pellet fueled barbeque grills sold to retailers, distributors, and direct to consumers. It produces and sells the pellets used to fire the grills and also sells Traeger-branded rubs, spices, and sauces, as well as grilling accessories including covers, barbeque tools, trays, liners, and merchandise. The company's geographical segments include North America and the Rest of the world, of which majority of revenue is from North America.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.